Therefore, AXL activation in TKI-resistant CML cells could be achieved by two different but complementary pathways, increased signaling or increased protein expression, both leading to resistance to TKIs. This evidence concerns the gene AXL and chronic myelogenous leukemia, BCR-ABL1 positive.